Tag Archives: Infliximab

Two-Drug Combo Doubles Crohn’s Disease Remission

April 8th, 2010 - 9:33 am

A study led by Mayo Clinic suggests remission from Crohn’s disease may be more likely if patients get biologic therapy, combined with immune-suppressing drugs first, instead of immune-suppressing drugs alone. The study, published in the April 15, 2010, issue of … Continue reading →

By Amy Tieder | Posted in Gastroenterology, Research | Tagged Azathioprine, Crohn's, Crohn's Disease, Infliximab, Sandborn, SONIC | Comments (7)

Crohn’s Disease Patients Benefit From Infliximab Plus Azathioprine

May 27th, 2009 - 2:29 pm

The use of infliximab (IFX) plus azathioprine (AZA) and infliximab monotherapy increase the likelihood of patients achieving long-term steroid-free clinical remission in patients with moderate to severe Crohn’s disease, according to a new study. This study represents the first time … Continue reading →

By Amy Tieder | Posted in Gastroenterology, Research | Tagged Azathioprine, Crohn's, IBD, Infliximab, Sandborn, SONIC | Leave a comment

Crohn’s Disease Study on Infliximab, Azathioprine

October 1st, 2008 - 9:12 pm

A study led by Mayo Clinic has found that infliximab (Remicade®) administered alone (monotherapy) or in combination with azathioprine is a more effective treatment for patients with moderate to severe Crohn’s disease than azathioprine alone. The findings were presented Oct. … Continue reading →